Added to YB: 2025-08-07
Pitch date: 2025-08-06
TEVA [neutral]
Teva Pharmaceutical Industries Limited
+73.39%
current return
Author Info
Kontra Investment Xchange is trying to build wealth by investing in good companies and letting those investments compound over many years. Sign up for the newsletter.
Company Info
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
Market Cap
$30.7B
Pitch Price
$55.31
Price Target
N/A
Dividend
N/A
EV/EBITDA
9.65
P/E
43.30
EV/Sales
2.72
Sector
Pharmaceuticals
Category
growth
Teva's ($TEVA) continued resurgence
TEVA (earnings update - bullish): 10 consecutive growth quarters + raised guidance. Key drugs Austedo, AJOVY, UZEDY all growing rapidly. 'Pivot to Growth' strategy delivers as innovative portfolio up 27%. Net debt cut to $15.1B (3.09x EBITDA), down from $34B peak. Pipeline includes olanzapine LAI & duvakitug ($2-5B potential). Cheap at 6.1x 2025 PE.
Read full article (6 min)